Metabolic disorder after androgen deprivation therapy in patients with prostate cancer.
10.3881/j.issn.1000-503X.2011.04.024
- Author:
Jia-qi YUAN
1
;
Xiao-wei ZHANG
;
Tao XU
;
Xiao-feng WANG
Author Information
1. Department of Urology, Peking University Peoples Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Androgen Antagonists;
adverse effects;
therapeutic use;
Humans;
Male;
Metabolic Diseases;
chemically induced;
Prostatic Neoplasms;
drug therapy;
metabolism
- From:
Acta Academiae Medicinae Sinicae
2011;33(4):468-472
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of prostate cancer, a common malignancy of urinary system in elderly males, has increased rapidly in China in recent years. Currently most prostate cancer patients are treated with androgen deprivation therapy (ADT). However, ADT-induced metabolic disorders such as metabolic syndrome has remarkably impaired the quality of life and decreased the survival rate.
